But Merck bought multiple biotechs and passed over DCVax-L every time. They don't need "complementary" therapies, they are all generic. Merck has seen all of DCVax-L data, is part of the UCLA SPORE trial so see all that data -- and still not buying it. They could buy NWBO with pocket change -- It's a damn $0.25 stock that is burning cash and has no capabilities to commercialize a drug.
Merck has never done a deal with an OTC biotech drug company as ANY BP. No BP trusts OTC as they have a reputation of being shady.
Market Data 
Markets 
AI
